Heather A. Wakelee, MD, of Stanford University Medical Center, discusses the primary disease-free survival results of IMpower010, a phase III study that compared adjuvant atezolizumab vs best supportive care after adjuvant chemotherapy in patients with early-stage resected non–small cell lung cancer (Abstract 8500).
Vamsidhar Velcheti, MD, of New York University, discusses overall survival and exploratory subgroup analyses from the phase II CodeBreaK 100 trial, which evaluated the use of...
Debora S. Bruno, MD, of Seidman Cancer Center at Cleveland Medical Center, discusses study findings that show Black patients with advanced or metastatic non–small cell lung c...
Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses results from the ADAPT HR–/HER2+ trial, which showed, for the first time, improved pathologic com...
Byoung Chul Cho, MD, PhD, of the Yonsei Cancer Center, discusses study results that showed treatment with the EGFR-MET bispecific antibody amivantamab plus the EGFR inhibitor...
